Navigation Links
Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide
Date:3/25/2008

life-threatening conditions, speeding treatment decisions and improving patient outcomes. SpHb may make hemoglobin testing quick, convenient and accessible to medical personnel in both acute and outpatient settings -- enabling them to quickly identify conditions of anemia, or blood loss. The availability of real-time continuous SpOC may help to ensure optimal oxygen delivery in patients during rapidly-changing clinical situations.

By continuously and noninvasively monitoring SpMet, clinicians can accurately determine if drugs they are administering are causing methemoglobinemia, which can lead to brain damage and even death. Similarly, the ability to measure SpCO allows clinicians to detect elevated levels of carboxyhemoglobin that can be caused by everything from desiccated soda lime (known as "Monday Morning Phenomena"), or other poisons that can be introduced during surgery, to smokers reporting for surgery with high SpCO values. Increased SpCO compromises healing and may lead to death, while smokers with residual elevated COHb at the time of anesthesia are at cardiac ischemic risk. PVI provides clinicians with a continuous and noninvasive quantified measurement of changes in the perfusion index -- indicating a change in a patient's physiologic condition, which may compromise cardiac function and affect systemic circulation -- with potential clinical applications for noninvasive hypovolemia detection and fluid responsiveness monitoring.

"Establishing Masimo Rainbow SET as the technology engine for Schiller's patient monitoring, emergency medicine and rescue solutions enables us to provide a dynamic new set of clinical capabilities that expand the physiological data and options available to clinicians and caregivers -- allowing them to better care for their patients," stated Dominik Doppler, VP, Marketing, Sales and Business Development at Schiller. "This is a compelling value proposition for the global healthcare market."

At the heart of Mas
'/>"/>

SOURCE Masimo
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Coley Pharmaceutical Group Adopts Shareholder Rights Plan
2. Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference
3. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
4. Masimo Announces Continuous Noninvasive Total Hemoglobin
5. Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group
6. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
7. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
8. Masimo to Report Third Quarter 2007 Financial Results on October 30, 2007
9. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
10. Masimo Reports Second Quarter 2007 Financial Results
11. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... critical, yet often overlooked factor in the medical ... effects of aggregation on both radiofrequency heating and ... oxide nanoparticles (IONPs), including detailed analysis of the ... is shown to produce significant reductions in both ... new method to quantify and correlate these effects ...
(Date:9/2/2014)... including University of Oregon chemist Geraldine Richmond, have ... self-assembling, synthetic proteins called peptoid nanosheets that mimic ... -- detailed this week in a paper placed ... of the National Academy of Sciences -- ... the two-dimensional peptoid nanosheets that can be used ...
(Date:9/2/2014)... , Sept. 2, 2014  TransCelerate BioPharma Inc. ... recommended approach for protecting personal data in Clinical ... patients and others. The document describes an approach ... from CSRs and other related clinical trial documents, ... The goal of the TransCelerate CSR Redaction approach ...
(Date:9/2/2014)... Opertech Bio, Inc., a company ... effective approach to sensory evaluation, today announced the ... U.S. Patent and Trademark Office, encompassing high-throughput sensory ... “Opertech’s taste evaluation technology called Microtiter Operant Gustometer ... system for rapid characterization of taste sensory properties,” ...
Breaking Biology Technology:Accounting for biological aggregation in heating and imaging of magnetic nanoparticles 2UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... Randomized Study Under Consideration, ROCKVILLE, Md., Nov. ... clinical-stage pharmaceutical company developing,therapeutics for the treatment of ... met the primary endpoint for the efficacy portion ... in combination with pemetrexed,(Alimta(R)) in non-small cell lung ...
... update on business and product pipeline, BOTHELL, ... Inc. (NASDAQ: OGXI ), a biopharmaceutical company ... that address,unmet needs in the treatment of cancer, ... and nine months ended September 30, 2008., ...
... 10 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group (NYSE: SCR ... generic,pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly,growing ... Morgan,Stanley 7th Annual Asia Pacific Summit 2008. The ... on November 11-13, 2008., Simcere,s chief financial ...
Cached Biology Technology:EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial 2EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial 3OncoGenex Reports Third Quarter Financial Results 2OncoGenex Reports Third Quarter Financial Results 3OncoGenex Reports Third Quarter Financial Results 4OncoGenex Reports Third Quarter Financial Results 5OncoGenex Reports Third Quarter Financial Results 6OncoGenex Reports Third Quarter Financial Results 7OncoGenex Reports Third Quarter Financial Results 8OncoGenex Reports Third Quarter Financial Results 9Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008 2
(Date:9/2/2014)... Yale Cancer Center researchers may have discovered a ... cells made vulnerable by deficient DNA repair. , The ... Reports . , The study, led by James ... Yale School of Medicine, found that cancer cells with ... their own genetic damage) were significantly more vulnerable to ...
(Date:9/2/2014)... digital distribution of media will have lower carbon ... when file sizes are large. , That,s the ... Journal of Industrial Ecology that looked at ... as PlayStation3. Researchers found that Blu-ray Discs delivered ... than game files downloaded over broadband Internet. For ...
(Date:9/2/2014)... 2, 2014 In a new study that could ... Florida campus of The Scripps Research Institute (TSRI) have ... unique manufacturing sites for molecules that can treat a ... as a reaction vessel and a disease-causing defect as ... cell," said TSRI Professor Matthew Disney.,"Because the treatment is ...
Breaking Biology News(10 mins):Sabotage as therapy: Aiming lupus antibodies at vulnerable cancer cells 2Scripps Florida scientists make diseased cells synthesize their own drug 2
... pathogens rather than kill them, and although they could be ... humans. A new study to be published in the online ... drugs have the potential to fight infection while avoiding the ... kill or stop the growth of pathogens, but antivirulence drugs ...
... Diego School of Medicine say that losing the ability to ... in early hominids, and may have directed the evolutionary emergence ... findings, published in this week,s early online edition of the ... among the first evidence of a novel link between cell ...
... York and Hull York Medical School has revealed important ... by age. Working with scientists at the Peninsula ... studied responses to stress in synapses -- neuronal connections. ... such as neuro-degeneration, resulting high energy forms of damaging ...
Cached Biology News:Can antivirulence drugs stop infections without causing resistance? 2Sexual selection by sugar molecule helped determine human origins 2Sexual selection by sugar molecule helped determine human origins 3Researchers study aging's effect on the brain 2
...
solute carrier family 25, member 13 (citrin)...
... Ladder is suitable for sizing ... 16 kb by agarose gel ... be visualized by ethidium bromide ... detected on Southern blots by ...
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: